Actively Recruiting
Phase II Study of Genakumab Injection for Safety and Effectiveness in Adults With Connective Tissue Disease-associated Interstitial Lung Disease
Led by Changchun GeneScience Pharmaceutical Co., Ltd. · Updated on 2025-01-17
30
Participants Needed
4
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of Genakumab injection in adults with connective tissue disease-associated interstitial lung disease CTD-ILD, including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. This Phase II randomized, double-blind, placebo-controlled study aims to better understand how Genakumab works in these conditions and assess its pharmacokinetic profile. Participants receive either Genakumab 300 mg or a placebo by subcutaneous injection every 4 weeks during a 24-week double-blind treatment period, totaling six doses. After this phase, all participants enter an open-label period where they receive Genakumab 300 mg every 4 weeks until the study ends or unacceptable toxicity or poor efficacy occurs. Injections are given in the abdomen, approximately 3 cm from the navel. Throughout the study, lung function is regularly assessed using forced vital capacity FVC, diffusion capacity for carbon monoxide DLCO, and Physicians Global Assessment scores at scheduled intervals from screening up to 2 years. Safety is monitored by recording adverse events during this time. Participants are followed closely with these tests and assessments to evaluate treatment effects and safety over the course of the trial.
CONDITIONS
Brief Title
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
Research Team
S
shengnan wen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here